Description
Anti-R-Spondin 1 Antibody, Non-Fucosylated (BioBet-1594ZP) is a human monoclonal IgG antibody against R-Spondin 1. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Cancer
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced R-Spondin 1 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
RSPO1
Full Name
R-spondin 1
Background
This gene encodes a secreted activator protein with two cysteine-rich, furin-like domains and one thrombospondin type 1 domain. The encoded protein is a ligand for leucine-rich repeat-containing G-protein coupled receptors (LGR proteins) and positively regulates the Wnt signaling pathway. In mice, the protein induces the rapid onset of crypt cell proliferation and increases intestinal epithelial healing, providing a protective effect against chemotherapy-induced adverse effects. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Apr 2014]
Alternative Names
RSPO1; R-spondin 1; RSPO; CRISTIN3; R-spondin-1; R-spondin homolog; roof plate-specific spondin-1;
Gene ID
284654
Cellular Localization
Extracellular region or secreted, Nucleus
Involvement in Disease
Diseases associated with RSPO1 include Palmoplantar Hyperkeratosis With Squamous Cell Carcinoma Of Skin And 46,Xx Sex Reversal and Hermaphroditism.
Related Pathways
Its related pathways are Signaling by GPCR and Signaling by Wnt.
Function
As the ligand of LGR4-6 receptor, it activates the typical Wnt signaling pathway (PubMed: 29769720). After binding to LGR4-6 (LGR4, LGR5 or LGR6), LGR4-6 binds to phosphorylated LRP6 and frizzled receptors activated by extracellular Wnt receptors, triggering a typical Wnt signaling pathway to increase the expression of target genes. It also regulates the canonical Wnt/ -catenin-dependent pathway and the non-canonical Wnt signal pathway by being an inhibitor of ZNRF3, an important regulator of the Wnt signaling pathway. As a ligand for curled FZD8 and LRP6. May negatively regulate the tgf-pathway. It plays an important role in the determination of ovaries. By interacting with KREM1, it antagonizes the internalization of LRP6 mediated by DKK1/KREM1 and regulates Wnt signaling.
Post-translational modifications
1.Glycosylation at Asn137 2.Modification sites at PhosphoSitePlus
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
BioBet-1594ZP
Description
The antibody that specifically bind human RSPO proteins are used for for treating diseases such as cancer.
Antibody Indication
Cancer
